Thus, the association between increased VEGF-D and ANG-2 levels and the acquisition of resistance to atezolizumab and bevacizumab for unresectable HCC is more relevant in patients without a history of systemic therapy. This evidence concerns the gene VEGFD and hepatocellular carcinoma.